Reports Q2 revenue $177,600, one estimate $180,000. “The positive outcome of our PALISADE-2 study demonstrated that fasedienol significantly reduced the mean Subjective Units of Distress Scale score, reducing anxiety during a stressful public speaking challenge. The study outcome is a pivotal achievement for fasedienol and our diverse pherine platform. These results mark the first positive U.S. Phase 3 study of an investigational therapy for social anxiety disorder in over 15 years,” said Shawn Singh, Chief Executive Officer of Vistagen. “We believe these results reinforce the promise of our pherine pipeline to address growing unmet treatment needs. We now move forward confidently advancing the Phase 3 program for fasedienol in SAD with planning for initiation of additional Phase 3 studies in 2024.”
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
See Insiders’ Hot Stocks on TipRanks >>
Read More on VTGN:
- VistaGen Therapeutics options imply 19.2% move in share price post-earnings
- Vistagen reports positive Phase 3 trial results of Fasedienol in SAD
- Vistagen up 29% as Commodore Capital increases position by $18M
- Biotech Alert: Searches spiking for these stocks today
- VistaGen Therapeutics trading resumes